검색결과

검색조건
좁혀보기
검색필터
결과 내 재검색

간행물

    분야

      발행연도

      -

        검색결과 534

        42.
        2023.05 구독 인증기관·개인회원 무료
        In response to a regulatory mandate, all nuclear licensees are obligated to establish an information system that can provide essential information in the event of a radiation emergency by connecting the monitoring data of the Safety Parameter Display System (SPDS) or equivalent system to the Korea Institute of Nuclear Safety (KINS). Responding to this responsibility, the Korea Atomic Energy Research Institute (KAERI) has established the Safety Information Transmission System (SITS), which enables the collection and real-time monitoring of safety information. The KAERI monitors and collects safety information, which includes data from the HANARO Operation Work Station (OWS) and the HANARO & HANARO Fuel Fabrication Plant (HFFP) Radioactivity Monitoring System (RMS), and the Environmental Radiation Monitoring System (ERMS) & meteorological data. Currently, the transmission of this safety information to the AtomCARE server of the KINS takes place via the SITS server located in the Emergency Operations Facility (EOF). However, the multi-path of transmission through SITS has caused problems such as an increase in data transmission interruptions and errors, as well as delays in identifying the cause and implementing system recovery measures. To address these issues, a new VPN is currently being constructed on the servers of nuclear facilities that generate and manage safety information to establish a direct transmission system of safety information from each nuclear facility to the AtomCARE server. The establishment of a direct transmission system that eliminates unnecessary transit steps is expected to result in stable information transmission and minimize the frequency of data transmission interruptions. As of the improvement progress, a security review was conducted in the second and third quarters of 2022 to evaluate the security of newly introduced VPNs to the nuclear facility server, and based on the results of the review, security measures were strengthened. In the fourth quarter of 2022, the development of a direct transmission system for safety information began, and it is scheduled to be completed by the fourth quarter of 2023. The project includes the construction of the transmission system, system inspection, and comprehensive data stability testing. Afterward, the existing SITS located in the EOF will be renamed as the Safety Information Display System (SIDS), and there are plans to remove any unused servers and VPNs.
        43.
        2023.05 구독 인증기관·개인회원 무료
        In-depth disposal of spent nuclear fuel means safe disposal of spent nuclear fuel by the concept of a multi-barrier system composed of an artificial barrier, an engineering barrier, and a natural barrier system of natural rock at a depth of less than 500 m underground. Disposal canisters are needed to store high-level waste in a deep environmental for a long time, and in order to demonstrate the performance of deep disposal canisters for spent nuclear fuel at underground research facilities (URL), it is intended to design disposal canisters and manufacture internal canisters. The internal canisters of spent nuclear fuel disposal canisters manufactured as a result of the study are combined with external copper canister technology and are directly used for demonstration of engineering barrier performance in underground facilities (URL) essential for final disposal of spent nuclear fuel. Disposal canister manufacturing technology and manufacturing process are used to manufacture disposal canisters for future final disposal projects in connection with domestic unique disposal systems. The quality inspection and quality management technology applied when manufacturing disposal canisters contribute to securing the soundness of disposal canisters that primarily maintain the safety of in-depth disposal by using them in the actual disposal business. By visually showing the development status of domestic disposal technology by displaying the prototype of disposal canisters manufactured as major achivements, the public can raise awareness of the domestic technology and safety of in-depth disposal of spent nuclear fuel.
        56.
        2022.12 KCI 등재 구독 인증기관 무료, 개인회원 유료
        Influenza A viruses (IAVs) are members of the family Orthomyxoviridae and genus Orthomyxovirus. Avian and mammalian species are the host of IAVs, which includes humans and dogs. Canine influenza virus (CIV) is an emerging pathogen that causes severe and acute respiratory diseases in dogs. This study monitored the antigen and antibody against CIV in dogs in the Republic of Korea (ROK) from 2016 to 2021. One thousand and seventy-two nasal swabs and 1,545 blood samples were collected from animal hospitals and animal shelters. Five nasal swabs in 2017 and seven in 2018 from stray dogs were positive for CIV according to RT-PCR. The prevalence of H3N2 CIV ranged from 9.5% to 24.8%, according to the hemagglutination inhibition (HI) assay. On the other hand, none of the serum samples from 2018 to 2021 showed seropositivity against the avian H5, H7, and H9 viruses. The HI titers for H3N2 ranged from 16 to 512. The distribution of HI titer 16–32 was 57.6% in seropositive samples. The pet dogs were vaccinated against CIV, but the stray and military dogs were unvaccinated. In 2017 and 2018, the seroprevalence of CIV in stray dogs was higher than in the other years, and viral RNA was detected in nasal swabs. It may mean previous exposure of stray dogs to CIV. With the increasing number of pet dogs and the close contact between humans and dogs, canines could serve as an intermediate host for transmitting IAVs to humans. Therefore, continuous surveillance of CIV is needed for public health and the potential emergence of novel zoonotic viruses.
        4,000원
        57.
        2022.12 KCI 등재 구독 인증기관 무료, 개인회원 유료
        Following the previous study, the toxicity of a single subcutaneous administration of the Thyrokitty injection (I-131) and the side effects that may occur at therapeutic doses were confirmed. The Thyrokitty injection (I-131) was administered subcutaneously once at a dose of 0, 2.0, 6.0, and 18.0 mCi/kg, 5 male and female rats per group, and mortality, general symptom observation, and weight measurement were performed for 2 weeks, followed by observation of autopsy findings. There were no deaths, and no statistically significant weight change was observed. Mild hair loss, fissures, and crusting were observed by general symptom observation, but it was not a toxic change related to the Thyrokitty injection (I-131). Gastric atrophy and a decrease in the size of the spleen were observed by the autopsy. As a results of single subcutaneous administration of the Thyrokitty Injection (I-131) to rats at a maximum dose of 18.0 mCi/kg, a decrease in the size of the spleen and gastric atrophy were observed as the dose of the Thyrokitty Injection (I-131) increased, which may be related to the test substance. No abnormal findings related to the Thyrokitty injection (I-131) were observed. Therefore, the approximate lethal dose of the Thyrokitty injection (I-131) was 18.0 mCi/kg or more. In addition, as reported for the treatment of feline hyperthyroidism with radioiodine (131I), side effects of the Thyrokitty injection (I-131) are expected to be extremely rare. Temporary dysphagia and fever may occur, but it will recover naturally. It should be administered with caution in cats with diseases such as urinary system, cardiovascular system, gastrointestinal system and endocrine system, especially with kidney disease. And it should not be used in cats who are pregnant, lactating, or likely. It is expected that the Thyrokitty injection (I-131) can be used for clinical treatment in Korea as a veterinary drug.
        4,200원
        58.
        2022.12 KCI 등재 구독 인증기관 무료, 개인회원 유료
        Radioiodine (131I) has been used for the treatment of feline hyperthyroidism since the 1990s in the USA and Europe, and it is recommended as the most effective treatment for feline hyperthyroidism because it has a high therapeutic effect, small side effects, and does not require anesthesia. In this study, the pharmacological properties of the Thyrokitty injection (I-131), which is being developed as a treatment for feline hyperthyroidism, using radioiodine (131I) as an active ingredient, was tested. The %cell uptake of the Thyrokitty injection (I-131) in FRTL- 5 thyroid cells was 0.410 ± 0.016%, which was about 18 times higher compared to Clone 9 hepatocytes, and it was decreased by 30.7% due to the competitive reaction with iodine (sodium iodide). In addition, the %cell growth of the FRTL-5 thyroid cells was reduced by 25.0% by treatment with the Thyrokitty injection (I-131). As a result of the tissue distribution test, the Thyrokitty injection (I-131) was distributed at the highest concentration at 0.083 hours (5 minutes) after subcutaneous administration to animals in most organs except the stomach, small intestine, large intestine, muscle and thyroid gland, and it was excreted mainly through the kidneys. The stomach and thyroid gland showed a typical distribution pattern observed when radioiodine (131I) was administered. In addition, about 78.45% of the total amount of excretion was excreted within 48 hours, of which more than 85% was excreted in urine. In conclusion, the Thyrokitty injection (I-131) has the same mechanism of action, potency, absorption, distribution, metabolism and excretion characteristics as radioiodine (131I) reported in connection with the treatment of feline hyperthyroidism. In the future, using the results of this study, it is expected that the Thyrokitty (I-131) could be safely used in the clinical treatment of feline hyperthyroidism.
        4,800원
        1 2 3 4 5